Navigation Links
Survival rates for pediatric bone marrow transplants top in nation
Date:1/26/2012

The UCSF Benioff Children's Hospital has the best overall survival rates in the nation for bone marrow transplants, according to a recent independent review of 156 programs nationwide.

The Pediatric Blood and Marrow Transplant Program, led by Morton Cowan, MD, was ranked number one for survival performance by the federally mandated review program of the Center for International Blood and Marrow Transplant Research (CIBMTR).

The 156 transplant centers were reviewed based on the number of transplants done annually, adjusted for risk, and estimated the chance for survival one year post transplant. Overall, the estimated chance of survival after one year was 63.4 percent. Of the 156 centers reviewed, only 14 (9 percent) were considered over performers, with the UCSF Pediatric Bone Marrow Transplant Program ranked number one with a survival rate of 87.6 percent.

Additionally, the Adult Hematology and Blood and Marrow Transplant (BMT) at UCSF Medical Center was again named an "over performer" by the CIBMTR. This is the second consecutive year the service has been recognized as an over performer. The adult program is also one of 14 nationwide recognized for exceeding U.S. expectations in patient survival rates for those undergoing a blood or marrow transplant from either a relative or an unrelated donor. At UCSF, 75 percent of adult patients receiving a BMT survive at least a year, compared to the national average of 63.4 percent.

Christopher Dvorak, MD, a pediatric blood and bone marrow transplant specialist at the UCSF Benioff Children's Hospital, wasn't surprised by the results knowing firsthand the level of commitment to success that exists within and well beyond the pediatric BMT team.

"We work incredibly hard and have an attention to detail and dedication to our policies attempting to limit transplant-associated mortality," said Dvorak, who is also head of the national Pediatric Blood and Marrow Transplant Consortium's Supportive Care Strategy Sroup.

The UCSF pediatric BMT program has expanded in recent years by adding two physicians and two nurse practitioners, ultimately increasing the number of transplants performed. UCSF's interdisciplinary collaboration among health care professionals also adds a nuanced level of support. "Some of the credit for our success must go to the pediatric intensive care unit which helps patients survive when then get critically ill," Dvorak said.

The pediatric BMT unit also gives more individualized attention to the dosing of chemotherapy medications through increased interactions with the UCSF School of Pharmacy. "We have a great School of Pharmacy and now have a doctor of pharmacy on our team, helping us with tailoring the chemo regimens. We have great nurses and nurse practitioners through the School of Nursing as well, and all of that plays into our success."

While adult bone marrow transplants are usually performed to treat blood-related cancers, pediatric transplants are necessary for a host of other reasons. Immunodeficiency syndromes, defects in red blood cells, inborn errors of metabolism, and several types of cancer account for many of the BMT transplants performed in children at UCSF.


'/>"/>
Contact: Juliana Bunim
juliana.bunim@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related medicine news :

1. Gene Mutations May Boost Ovarian Cancer Survival: Study
2. Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years
3. Study showed oxaliplatin improved colon cancer patient survival
4. Drug improves survival of colorectal cancer patients, trial results show
5. Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
6. Personalized gene therapies may increase survival in brain cancer patients
7. Race, Gender, Dementia May Affect Parkinsons Survival
8. Demographic and clinical factors appear associated with survival in patients with Parkinsons disease
9. Ovarian cancer study proves drug delays disease progression, may improve survival
10. Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
11. Researchers identify potential target to delay metastatic pancreatic cancer and prolong survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Survival rates for pediatric bone marrow transplants top in nation
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: